ARCA biopharma GAAP EPS of -$0.16

Oct. 28, 2022 4:18 PM ETARCA biopharma, Inc. (ABIO)By: Pranav Ghumatkar, SA News Editor
  • ARCA biopharma press release (NASDAQ:ABIO): Q3 GAAP EPS of -$0.16.
  • Cash and cash equivalents were $43.9 million as of September 30, 2022, compared to $53.4 million as of December 31, 2021.
  • ARCA believes that its current cash and cash equivalents, will be sufficient to fund its operations at the current levels through at least the end of 2023.
  • The Company’s review of its strategic options may impact this projection.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.